Patent ID: 8247175

Claim:
A method of screening for decreased risk of primary graft failure of a lung transplant, comprising the steps: (a) obtaining a sample of a human donor lung; (b) determining the level of RNA product of one or more biomarkers selected from the biomarkers human microephaly, autosomal recessive 1 (MCPH1), human fibroblast growth factor receptor 2 (FGFR2), human ATPase, Class VI, type 11B (ATP11B) and human Egl nine homolog 1 (EGLN1) in said sample; (c) comparing the level of one or more RNA products in the sample with levels in control lung samples of human patients which survived less than 30 days after lung transplant; and (d) detecting statistically significant decreased expression of the RNA product or products between the donor lung and the control lung samples, wherein a statistically significant decreased expression has a p-value less than 0.05, by a Student's t-test and identifying the donor lung with said statistically significant decreased expression as having decreased risk for primary graft failure relative to a human donor lung that does not have said decreased expression.